Abstract

STERIS plc is scheduled to release fiscal 2027 first‑quarter results on August 5, 2026, Post Market; consensus points to revenue of 1.50 billion US dollars (up 9.90% year over year) and adjusted EPS of 2.50 (up 10.54% year over year), with our preview detailing segment dynamics, margin watch items, and what analysts will focus on.

Market Forecast

For the fiscal 2027 first quarter, market expectations indicate revenue of 1.50 billion US dollars, representing 9.90% year‑over‑year growth, and adjusted EPS of 2.50, up 10.54% year over year; EBIT is projected at 341.98 million US dollars, up 11.67% year over year. Forecast granularity for gross profit margin and net profit margin is not available, and no formal guidance for those metrics was provided alongside the consensus figures.

Within the company’s portfolio, the Healthcare business remains the largest revenue contributor and continues to benefit from steady procedural volumes and a solid order book; management has emphasized continued investment in capacity and efficiency, and cost control. The Applied Sterilization Technologies business stands out for growth potential this quarter, supported by a sizable revenue base of 289.20 million US dollars last quarter and favorable backlog trends, while the company continues to prioritize operational execution; year‑over‑year segment growth detail was not disclosed.

Last Quarter Review

In the most recent reported quarter, STERIS plc delivered revenue of 1.59 billion US dollars (up 7.29% year over year), a gross profit margin of 43.93%, GAAP net income attributable to shareholders of 220.00 million US dollars with a net profit margin of 13.86%, and adjusted EPS of 2.83 (up 3.29% year over year). Quarter on quarter, net income increased by 14.15%.

A key financial highlight was EBIT of 384.90 million US dollars, growing 4.70% year over year, reflecting disciplined operating cost management amid inflationary inputs. On the commercial side, the Healthcare segment contributed 1.14 billion US dollars, representing 71.54% of quarterly revenue, while Applied Sterilization Technologies contributed 289.20 million US dollars (18.21%) and Life Sciences contributed 162.90 million US dollars (10.26%); year‑over‑year growth by segment was not disclosed in the last quarter’s breakdown.

Current Quarter Outlook

Main business: Healthcare

The Healthcare business remains the primary revenue engine, underpinned by a quarterly revenue base of 1.14 billion US dollars in the previous period and a clear share of 71.54% of the mix. Into the fiscal 2027 first quarter, consensus suggests the company can deliver total revenue growth of 9.90% year over year, and this pace will rely on stable utilization of capital equipment and consumables across customer settings, along with service execution. The absence of margin‑specific guidance for the quarter places emphasis on the realized mix within Healthcare, where service and consumables typically offer steadier gross margin than large equipment cycles; maintaining a gross margin profile near the recent 43.93% baseline would support the projected adjusted EPS expansion to 2.50.

Execution milestones this quarter include timely conversion of the existing order book into shipments and continued cost discipline. Management commentary during recent updates highlighted attention to capacity and efficiency investments and a commitment to cost control, which supports EBIT leverage in line with the 11.67% year‑over‑year EBIT growth embedded in consensus for the quarter. Assuming equipment shipments track plan and consumables demand remains resilient, Healthcare’s contribution should be the principal determinant of whether the company matches or surpasses the EPS trajectory signaled by consensus.

Given the Healthcare segment’s scale, modest shifts in backlog timing or installation schedules can move revenue across fiscal periods. Investors should therefore monitor any color management provides on shipment timing in the quarter. On the profitability side, supply chain normalization—if sustained—helps protect gross margin, while inflationary inputs remain a watch item. A stable to slightly expanding operating margin inside Healthcare would go a long way toward validating the mid‑to‑high single‑digit top‑line growth and double‑digit EPS growth embedded in consensus.

Most promising business: Applied Sterilization Technologies

Applied Sterilization Technologies contributed 289.20 million US dollars in the last reported quarter and remains a visible growth candidate in the near term based on its consistent demand backdrop and the company’s stated intention to invest in capacity and efficiency. While quarter‑specific year‑over‑year growth for the segment was not disclosed, backlog updates and past performance indicate durable throughput, and the company’s commentary on augmenting growth through selective acquisitions provides incremental optionality. In the context of the quarter’s overall forecasts—revenue growth of 9.90% and adjusted EPS growth of 10.54%—incremental volume and utilization gains in this segment can reinforce the consolidated growth algorithm.

Margin translation from this business into consolidated earnings is a focal point this quarter. If capacity additions and operational improvements track plan, the business can contribute positive operating leverage, which is consistent with the consensus view that EBIT will grow 11.67% year over year to 341.98 million US dollars. Given the lack of published margin guidance by segment, the key marker will be whether consolidated gross margin trends hold near the prior quarter’s 43.93% while the company scales throughput.

Investors should also watch management’s update on capital deployment and any commentary on pipeline opportunities, as the business’s long‑term trajectory is supported by expansions and targeted M&A. In the near term, the conversion of orders and scheduling efficiency are the practical gates. If those flow smoothly, the segment’s performance should bolster the company’s ability to land near the mid‑point of EPS expectations despite the seasonal patterns that can appear in early fiscal quarters.

Key swing factor for shares this quarter

The most consequential swing factor for the stock into the print is the interplay between mix‑driven gross margin and operating leverage versus cost inflation and shipment timing. With the previous quarter’s gross margin at 43.93% and net profit margin at 13.86%, investors will scrutinize whether consolidated margins can remain stable even as revenue mix evolves between equipment, consumables, service, and sterilization throughput. Visibility into quarterly ordering and installation patterns—particularly for larger capital placements—can shift revenue recognition, influencing the quarter’s reported trajectory against expectations.

Consensus expects adjusted EPS of 2.50 (up 10.54% year over year) on 1.50 billion US dollars of revenue (up 9.90% year over year), which implies modest operating leverage. The realized conversion from backlog, coupled with ongoing cost controls, will be the deciding factors in achieving the expected EBIT of 341.98 million US dollars. Management has previously emphasized investments in capacity and efficiency; investors will look for evidence that these investments are paying off in the form of throughput consistency and cost capture.

Finally, cash discipline remains a secondary but meaningful consideration. Recent company updates referenced healthy operating and free cash flow and a conservative balance sheet profile; continuation of that pattern, even in the face of capex for capacity, would support valuation resilience. Any deviation—such as higher‑than‑expected working capital draw due to shipment timing—could temporarily weigh on free cash flow conversion metrics for the quarter but would not necessarily change the underlying demand picture if backlogs remain constructive.

Analyst Opinions

The current sell‑side stance is predominantly bullish based on recent ratings and target updates gathered within the noted time frame, with a 100% skew toward positive views among the tracked items. UBS initiated coverage with a Buy rating and a 275 US dollars price target in late July, citing confidence in execution and the earnings trajectory that aligns with the quarter’s consensus for 9.90% revenue growth and 10.54% adjusted EPS growth. Stephens maintained an Overweight rating while adjusting its price target to 240 US dollars in July, pointing to solid fundamentals and a reasonable risk‑reward as the company enters the new fiscal year’s first quarter. Piper Sandler maintained an Overweight rating with a 270 US dollars target in May, underscoring expectations for continued earnings progression in line with mid‑to‑high single‑digit revenue growth and operating discipline.

These institutions collectively expect STERIS plc to deliver on its double‑digit adjusted EPS growth outlook for the quarter via a combination of steady top‑line expansion and operating leverage. The consensus 341.98 million US dollars EBIT estimate, up 11.67% year over year, is a focal marker for the Street; meeting or exceeding this threshold would validate the thesis that margin resilience can be maintained near the recent gross margin print of 43.93% while scaling revenue to roughly 1.50 billion US dollars. Analysts also highlight the durability of demand patterns reflected in the company’s recent order and backlog commentary and the contribution from operational efficiency investments.

In synthesizing the majority view, the Street’s bullishness is grounded in the expectation that the company can manage cost inflation and shipment timing to land within the indicated revenue and EPS ranges. Should the company confirm revenue near 1.50 billion US dollars and adjusted EPS near 2.50, and offer constructive qualitative color on backlog conversion, capacity utilization, and cost control, analysts anticipate that estimates for the remainder of fiscal 2027 will be well supported. Conversely, the primary watch items into the print are the quarter’s realized mix and any transitory timing effects that could bridge revenue between the first and second quarters; the tone of management’s August 5, 2026 Post Market update will therefore be closely parsed for indications on cadence into the balance of the fiscal year.

Overall, the weight of institutional commentary suggests the bias of expectations is positive into the quarter. With growth estimates of 9.90% for revenue and 10.54% for adjusted EPS, and with forecast EBIT up 11.67% year over year, the bar is not set unreasonably high, yet it does require continued execution on costs and conversion. The majority view is that the company’s operational track record and the scale of its Healthcare and sterilization businesses provide a foundation to meet these goals, reinforcing bullish ratings and supportive price targets heading into the results.